Skip to content

CBD research published in 2022

21 studies whose primary subject is CBD were published in 2022, up from 16 in 2021. Newest first. Back to the CBD overview

Studies

Genetic substrates of cannabis-associated psychosis

Revista Española de Drogodependencias December 30, 2022 Diego Quattrone

This paper will summarise the main substrates of cannabis-associated psychoses. First, an epistemological framework will be introduced to support the existence of a specific ‘cannabisassociated psychosis’ as a nosological entity distinct from idiopathic schizophrenia and other psychotic disorders. Then, the main clinical characteristics of cannabis-associated psychoses will be examined....

DOI: 10.54108/10030 (opens in new tab) Cannabidiol Psychosis Schizophrenia object-oriented programming Effects of cannabis +1

Effects of Cannabidiol and Delta-9-Tetrahydrocannabinol on Plasma Endocannabinoid Levels in Healthy Volunteers: A Randomized Double-Blind Four-Arm Crossover Study

Cannabis and Cannabinoid Research December 9, 2022 Lucy Chester, Amir Englund, Edward Chesney et al. 20 citations

Background: The effects of cannabis are thought to be mediated by interactions between its constituents and the endocannabinoid system. Delta-9-tetrahydrocannabinol (THC) binds to central cannabinoid receptors, while cannabidiol (CBD) may influence endocannabinoid function without directly acting on cannabinoid receptors. We examined the effects of THC coadministered with different doses of CBD...

Cannabinoid treatments for anxiety: A systematic review and consideration of the impact of sleep disturbance.

Neuroscience & Biobehavioral Reviews December 2022 Andrea J Narayan, Luke A. Downey, Brooke Manning et al.

Cannabidiol's (CBD) safety profile and broad action has made it a popular treatment option for anxiety and co-occurring sleep disturbance. However, its efficacy in healthy and clinical populations, treatment duration, formulation and doses for optimal therapeutic benefits remains unclear. Selected databases were examined from inception to October 2022. Study selection, data extraction and...

Differential Enantiomer-Specific Signaling of Cannabidiol at CB1 Receptors.

Molecular Pharmacology December 2022 Taryn Bosquez-Berger, Sierra Wilson, Christos Iliopoulos-Tsoutsouvas et al.

The two main constituents of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). While Δ9-THC pharmacology has been studied extensively, CBD-long considered inactive-is now the subject of vigorous research related to epilepsy, pain, and inflammation and is popularly embraced as a virtual cure-all. However, our understanding of CBD pharmacology remains limited, although CBD...

Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios

Neuropsychopharmacology November 16, 2022 Amir Englund, D. Oliver, Edward Chesney et al.

As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful effects of cannabis use. This study aimed to determine if increasing the CBD content of cannabis can reduce its harmful effects. Forty-six healthy, infrequent cannabis users participated in a double-blind, within-subject, randomised trial of cannabis preparations...

Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis

Psychopharmacology October 13, 2022 Nadia R. P. W. Hutten, Thomas R. Arkell, Frederick Vinckenbosch et al. 36 citations

RATIONALE: Delta-9-tetrahydrocannabinol (THC), an active component of cannabis, can cause anxiety in some users during intoxication. Cannabidiol (CBD), another constituent of cannabis, has anxiolytic properties suggesting that cannabis products containing CBD in addition to THC may produce less anxiety than THC-only products. Findings to date around this issue have been inconclusive and could...

Sex Differences in the Neuropsychiatric Effects and Pharmacokinetics of Cannabidiol: A Scoping Review.

Biomolecules October 12, 2022 Justin Matheson, Zoe Bourgault, Bernard Le Foll

Cannabidiol (CBD) is a non-intoxicating cannabinoid compound with diverse molecular targets and potential therapeutic effects, including effects relevant to the treatment of psychiatric disorders. In this scoping review, we sought to determine the extent to which sex and gender have been considered as potential moderators of the neuropsychiatric effects and pharmacokinetics of CBD. In this...

[Cannabidiol pharmacotherapy for delta-9-tetrahidrocannabinol dependence].

Vertex Revista Argentina de Psiquiatría October 10, 2022 Federico Pavlovsky, Rafael Groisman, Ana Karina Hurtado et al.

Addictions are one of the most important health problems worldwide. Within these disorders, cannabis is one of the psychoactive substances with more burden of morbidity and mortality worldwide. The actual knowledge about the effectiveness of treatments for cannabis use disorders is unsatisfactory. This review aims to explore the evidence on cannabidiol for the treatment of cannabis use...

Association between formal thought disorder and cannabis use: a systematic review and meta-analysis

Schizophrenia September 29, 2022 Mathilde Argote, Guillaume Sescousse, Jérôme Brunelin et al. 7 citations

Formal thought disorder (FTD) is a multidimensional syndrome mainly occurring along the psychosis continuum. Cannabis use is known to increase symptoms of psychosis, particularly positive symptoms. However, the impact of cannabis use on FTD in individuals presenting symptoms along the psychosis continuum remains unclear. To address this knowledge gap, we conducted a meta-analysis examining the...

The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study

Cannabis and Cannabinoid Research July 26, 2022 Alberto Sainz-Cort, Daniel Jiménez‐garrido, Elena Muñoz Marrón et al. 9 citations

Background: Social cognition abilities such as empathy and the Theory of Mind (ToM) have been shown to be impaired in neuropsychiatric conditions such as psychotic, autistic, and bipolar disorders. The endocannabinoid system (ECS) seems to play a role in social behavior and emotional processing while it also seems to play a role in those neuropsychiatric conditions showing social cognition...

Differences in Inhibitory Control and Resting Brain Metabolism between Older Chronic Users of Tetrahydrocannabinol (THC) or Cannabidiol (CBD)—A Pilot Study

Brain Sciences June 23, 2022 Thorsten Rudroff, Craig D. Workman, Phillip E. Gander et al. 3 citations

Δ9-Tetrahydrocannabinol is the main psychoactive component of cannabis and cannabidiol is purportedly responsible for many of the medicinal benefits. The effects of Δ9-tetrahydrocannabinol and cannabidiol in younger populations have been well studied; however, motor function, cognitive function, and cerebral glucose metabolism in older adults have not been extensively researched. The purpose of...

Individual and combined effects of cannabidiol and Δ 9 -tetrahydrocannabinol on striato-cortical connectivity in the human brain

Journal of Psychopharmacology May 20, 2022 Matthew B. Wall, Tom P. Freeman, Chandni Hindocha et al. 21 citations

Background: Cannabidiol (CBD) and Δ 9 -tetrahydrocannabinol (THC) are the two major constituents of cannabis with contrasting mechanisms of action. THC is the major psychoactive, addiction-promoting, and psychotomimetic compound, while CBD may have opposite effects. The brain effects of these drugs alone and in combination are poorly understood. In particular, the striatum is implicated in the...

Alternative Options for Complex, Recurrent Pain States Using Cannabinoids, Psilocybin, and Ketamine: A Narrative Review of Clinical Evidence

Neurology International May 18, 2022 Amber N. Edinoff, Juliana M. Fort, Christina Singh et al. 15 citations

With emerging information about the potential for morbidity and reduced life expectancy with long-term use of opioids, it is logical to evaluate nonopioid analgesic treatments to manage pain states. Combinations of drugs can provide additive and/or synergistic effects that can benefit the management of pain states. In this regard, tetrahydrocannabinol (THC) and cannabidiol (CBD) modulate...

Cannabis Use and Neuroadaptation: A Call for Δ9-Tetrahydrocannabinol Challenge Studies

Frontiers in Psychiatry April 14, 2022 Johannes G. Ramaekers, Eef L. Theunissen, Peter van Ruitenbeek et al. 6 citations

Currently, the assessment of the neurobehavioral consequences of repeated cannabis use is restricted to studies in which brain function of chronic cannabis users is compared to that of non-cannabis using controls. The assumption of such studies is that changes in brain function of chronic users are caused by repeated and prolonged exposure to acute cannabis intoxication. However, differences in...

DOI: 10.3389/fpsyt.2022.870750 (opens in new tab) Cannabidiol Effects of cannabis Neurocognitive Delta-9-tetrahydrocannabinol +3

Prosocial Effects of Nonpsychotropic Cannabis sativa in Mice.

Cannabis and Cannabinoid Research April 2022 Andrea Mastinu, Roberta Ascrizzi, Giovanni Ribaudo et al.

Introduction:Cannabis sativa L. (C. sativa) is used since ancient times to produce fabrics, baskets, and cords. Later, different ethnic groups used to burn the leaves and flowers of psychotropic cultivars with high Δ9-tetrahydrocannabinol (D9-THC) levels, during the religious or propitiatory rites to alter the state of consciousness. To date, it is not known whether also nonpsychotropic...

Functional brain connectomes reflect acute and chronic cannabis use

Scientific Reports February 14, 2022 Johannes G. Ramaekers, Natasha L. Mason, Stefan W. Toennes et al. 26 citations

Resting state fMRI has been employed to identify alterations in functional connectivity within or between brain regions following acute and chronic exposure to Δ9-tetrahydrocannabinol (THC), the psychoactive component in cannabis. Most studies focused a priori on a limited number of local brain areas or circuits, without considering the impact of cannabis on whole-brain network organization....

[Pharmacology of cannabidiol: Red flags, consequences and risks in humans].

The´rapie 2022 Joëlle Micallef, Anne Batisse, Bruno Revol

Scientific knowledge about cannabidiol (CBD) demonstrates that CBD is a substance that is not pharmacologically inert. If it does not act efficiently on cannabinoid receptors (those where tetrahydrocannabidol [THC] is fixed), it acts on brain receptors, especially on dopamine and serotonin receptors, making it a psychoactive product in its own right. Its consumption can thus have psychoactive...

The Relationship Between Cannabis, Cognition, and Schizophrenia: It’s Complicated

Current Topics in Behavioral Neurosciences 2022 Hakan Kayır, Jessica Ruffolo, Patrick McCunn et al. 15 citations

America and across the globe. Cannabis use has multifaceted impacts on cognition in schizophrenia patients and healthy subjects. Healthy subjects, particularly those who initiated cannabis use at earlier ages and used high-potency cannabis for longer durations, exhibited poorer cognition mainly in working memory and attention. Cannabis use in schizophrenia has been associated with symptom...

DOI: 10.1007/7854_2022_396 (opens in new tab) Cannabidiol Effects of cannabis Cognition Schizophrenia object-oriented programming +3

Effects of cannabidiol in cannabis flower: Implications for harm reduction.

Addiction Biology 2022 Laurel P Gibson, Hollis C Karoly, Jarrod M. Ellingson et al.

Using a federally compatible, naturalistic at-home administration procedure, the present study examined the acute effects of three cannabis flower chemovars with different tetrahydrocannabinol (THC) to cannabidiol (CBD) ratios, in order to test whether chemovars with a higher CBD content produce different effects. Participants were randomly assigned to ad libitum administration of one of three...

Associations Between Cannabis, Psychosis, and Schizophrenia in Adolescents

Academic Leadership Journal in Student Research 2022 Lauren Moment, Null Null 2 citations

The effects of cannabis use on the brain, mind, and body have been studied for decades. The developing brain, particularly the adolescent and young adult brain, undergoes critical development that makes it especially susceptible to the effects of cannabis use. Among the adverse effects of cannabis use in adolescence and young adulthood, psychosis and psychotic disorders (e.g., schizophrenia)...

DOI: 10.58809/dbkn1868 (opens in new tab) Cannabidiol Psychosis Schizophrenia object-oriented programming Effects of cannabis +3